Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 56, Issue 3, Pages 436-443Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.114.145011
Keywords
Cu-labeled diacetyl-bis (N4-methylthiosemicarbazone) PET; 16 alpha-F-18-fluoro-17 beta-estradiol PET; diffusion weighted imaging; dynamic contrast enhanced MRI; perfusion MRI
Ask authors/readers for more resources
MR imaging and F-18-FDG PET/CT play central and complementary roles in the care of patients with gynecologic cancer. Because treatment often requires combinations of surgery, radiotherapy, and chemotherapy, imaging is central to triage and to determining prognosis. This article reviews the use of the 2 imaging modalities in the initial evaluation of 3 common cancers: uterine cervical, uterine endometrial, and epithelial ovarian. Imaging features that affect management are highlighted, as well as the relative strengths and weaknesses of the 2 modalities. Use of imaging after initial therapy to assess for recurrence and to plan salvage therapy is described. Newer functional and molecular techniques in MR imaging and PET are evaluated. Finally, we describe our initial experience with PET/MR imaging, an emerging technology that may prove to be a mainstay in personalized gynecologic cancer care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available